3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1/2
2
Phase 4
1
Phase 3
1
Phase 2/3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Whole-Brain Radiotherapy
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Ovarian Neoplasms
1
Nasopharyngeal Carcinoma
1
Lung Neoplasms
1
Leiomyosarcoma
1
Fallopian Tube Neoplasms
1
Extensive Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced Renal Cancer
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Doxorubicin
25
Ifosfamide
22
Radiotherapy
17
Etoposide
11
Vincristine
10
Cyclophosphamide
10
Filgrastim
8
Dactinomycin
8
Trabectedin
7
Chemotherapy, Adjuvant
5
pazopanib
4
Cisplatin
4
Topotecan
3
Radiation
3
Neoadjuvant Therapy
3
Irinotecan
3
Granulocyte Colony-Stimulating Factor
3
Dacarbazine
3
sargramostim
2
etoposide phosphate
2
eribulin
2
Observation
2
Methotrexate
2
Mesna
2
Imatinib Mesylate
2
Gemcitabine
2
Epirubicin
2
Docetaxel
2
Dexrazoxane
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Sarcoma
×
anlotinib
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled